30.80
Viking Therapeutics Inc Aktie (VKTX) Neueste Nachrichten
Viking Therapeutics (NASDAQ: VKTX) shareholders back directors, auditor and pay - Stock Titan
If Viking Therapeutics Is Acquired, Here’s Who Wins - AOL.com
Prediction: These 2 Obesity Drug Stocks Could Double in 2026 - AOL.com
Is Viking Therapeutics (VKTX) Pricing In Too Much Optimism After Recent Share Price Swings? - simplywall.st
Prediction: These 2 Obesity Drug Stocks Could Double in 2026 - The Motley Fool
Don't buy Viking Therapeutics stock until you read this - MSN
Don't Buy Viking Therapeutics Stock Until You Read This - The Motley Fool
Could Viking Therapeutics Be the Next Eli Lilly? - AOL.com
A Look At Viking Therapeutics (VKTX) Valuation As Shares Show Mixed Recent Returns - Yahoo Finance
Is Viking Therapeutics a Top Takeover Target? - The Motley Fool
Should New Phase 2 Oral VK2735 Weight-Loss Data Require Action From Viking Therapeutics (VKTX) Investors? - simplywall.st
Viking Therapeutics, Inc. Stock 12‑Month Price Target Raised to $95.4, Implies 209% Upside - TradingView
Viking Therapeutics Analyst Ratings and Price Targets | NASDAQ:VKTX - Benzinga
2 Stocks That Could Realistically Double by 2030 - The Motley Fool
VKTX Technical Analysis | Trend, Signals & Chart Patterns | VIKING THERAPEUTICS INC (NASDAQ:VKTX) - ChartMill
Viking Therapeutics faces timeline risk, but upside could be huge - MSN
Viking Therapeutics to Participate at Upcoming Investor Conferences - StreetInsider
VKTX Stock Chart | VIKING THERAPEUTICS INC (NASDAQ:VKTX) - ChartMill
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics' Pill Could Crash the Weight-Loss Party - The Globe and Mail
Three Biotechs That Are Top Takeover Targets - 24/7 Wall St.
Viking Therapeutics, Inc.Common Stock (NQ: VKTX - The Chronicle-Journal
VKTX stock slips premarket: A surprise weight loss drug beats Novo Nordisk in early animal tests - MSN
Viking Therapeutics, Inc. (VKTX) declines more than market: Some information for investors - MSN
The Bull Case For Viking Therapeutics (VKTX) Could Change Following New Oral VK2735 Obesity Data Release - Yahoo Finance
Avoiding Lag: Real-Time Signals in (VKTX) Movement - Stock Traders Daily
symbol__ Stock Quote Price and Forecast - CNN
How New Oral VK2735 Obesity Data At Viking Therapeutics (VKTX) Has Changed Its Investment Story - simplywall.st
VKTX Q1 earnings miss on higher phase 3 development costs - MSN
Viking Therapeutics (VKTX) Valuation Revisited After New VK2735 Phase 2 Obesity Data Spurs Investor Interest - simplywall.st
Viking Therapeutics (VKTX) Reveals Promising Phase 2 Trial Resul - GuruFocus
Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTU - GuruFocus
Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026 - PR Newswire
Patients on experimental obesity drug lost up to 26.6 lb in 13 weeks - Stock Titan
Earnings call transcript: Viking Therapeutics Q1 2026 sees widened net loss - Investing.com India
Earnings call transcript: Viking Therapeutics Q1 2026 sees widened net loss By Investing.com - Investing.com South Africa
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):